Compared with the difference in efficacy between EGFR-TKIs alone and EGFR-TKIs combined with craniocerebral radiotherapy in EGFR mutant lung adenocarcinoma patients with brain metastasis. A propensity-score matched analysis

被引：0
|
作者：
Deng, G. [1 ]
Li, Z. [1 ]
机构：
[1] Shandong Univ, Shandong Canc Hosp, Jinan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1128
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1002P
引用
收藏
页码：S1012 / S1012
页数：1
相关论文
共 50 条
  • [31] Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway
    Wu, Hongyan
    Fan, Fangtian
    Liu, Zhaoguo
    Shen, Cunsi
    Wang, Aiyun
    Lu, Yin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (02) : 307 - 315
  • [32] USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma
    Zhang, Huijuan
    Han, Bing
    Lu, Hailing
    Zhao, Yanbin
    Chen, Xuesong
    Meng, Qingwei
    Cao, Mengru
    Cai, Li
    Hu, Jing
    CANCER LETTERS, 2018, 433 : 186 - 198
  • [33] TTF-1 Expression as a Predictor of Response to EGFR-TKIs in Patients with Lung Adenocarcinoma
    Syrigos, Kostas
    Sarris, Evangelos
    Kotteas, Ilias
    Fotopoulos, Georgios
    Vamvakaris, Loannis
    Trigidou, Rodoula
    Grapsa, Dimitra
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1197 - S1197
  • [34] The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs
    Gu, Weiguo
    Liu, Penghui
    Tang, Jiaming
    Lai, Jianfei
    Wang, Siya
    Zhang, Jiaming
    Xu, Jinbiao
    Deng, Jianxiong
    Yu, Feng
    Shi, Chao
    Qiu, Feng
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [35] Comparing the efficacy of two generations of EGFR-TKIs: An integrated drug-disease mechanistic model approach in EGFR-mutant lung adenocarcinoma
    Monteiro, Claudio
    Darre, Hippolyte
    Masson, Perrine
    Nativel, Arnaud
    Villain, Laura
    Lefaudeux, Diane
    Couty, Claire
    Martin, Bastien
    Jacob, Evgueni
    Duruisseaux, Michael
    Palgen, Jean-Louis
    L'Hostis, Adele
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer
    Sheng, Zhixin
    Zhang, Yanxia
    MEDICAL ONCOLOGY, 2015, 32 (01) : 1 - 7
  • [37] The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Chin, Chun-Shih
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Chen, Kun-Chieh
    Su, Kang-Yi
    Yu, Sung-Liang
    Chen, Jeremy J. W.
    Chang, Gee-Chen
    CANCER RESEARCH AND TREATMENT, 2022, 54 (02): : 434 - 444
  • [38] EGFR-TKIs Combined Hydroxycamptothecin Improved Outcomes in EGFR-Mutant NSCLC Patients Who Harboring Pericardial Effusion
    Wang, X.
    Yao, J.
    Guo, R.
    Lu, X.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S985 - S985
  • [39] AFATINIB IN EGFR MUTANT NON-SMALL-CELL LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE TO REVERSIBLE EGFR-TKIS
    Cappuzzo, Federico
    Tiseo, Marcello
    Chiari, Rita
    Landi, Lorenza
    Ricciardi, Serena
    Rossi, Elisa
    Galetta, Domenico
    Novello, Silvia
    Milella, Michele
    D'Incecco, Armida
    Haspinger, Eva Regina
    Cortinovis, Diego
    Santo, Antonio
    Banna, Giuseppe
    Facchi-Netti, Francesco
    Levra, Matteo Giaj
    Vari, Sabrina
    Crino, Lucio
    De Marinis, Filippo
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S610 - S610
  • [40] EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer
    Zhixin Sheng
    Yanxia Zhang
    Medical Oncology, 2015, 32
12345